The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery
Open accessAbstract
BACKGROUND: The efficacy and safety of oral ulipristal acetate for the treatment of symptomatic uterine fibroids before surgery are uncertain. METHODS: We randomly assigned women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood-loss assessment chart [PBAC, an objective assessment of blood loss, in which monthly scores range from 0 to >500, with higher numbers indicating more bleeding]) and anemia (hemoglobin level of ≤10.2 g per deciliter) to receive treatment for up to 13 weeks with oral ulipristal acetate at a dose of 5 mg per day (96 women) or 10 mg per day (98 women) or to receive placebo (48 women). All patients received iron supplementation. The coprimary efficacy end points were control of uterine bleeding (PBAC score of <75) and reduction of fibroid volume at week 13, after which patients could undergo surgery. RESULTS: At 13 weeks, uterine bleeding was controlled in 91% of the women receiving 5 mg of ulipristal acetate, 92% of those receiving 10 mg of ulipristal acetate, and 19% of those receiving placebo (P<0.001 for the comparison of each dose of ulipristal acetate with placebo). The rates of amenorrhea were 73%, 82%, and 6%, respectively, with amenorrhea occurring within 10 days in the majority of patients receiving ulipristal acetate. The median changes in total fibroid volume were -21%, -12%, and +3% (P=0.002 for the comparison of 5 mg of ulipristal acetate with placebo, and P=0.006 for the comparison of 10 mg of ulipristal acetate with placebo). Ulipristal acetate induced benign histologic endometrial changes that had resolved by 6 months after the end of therapy. Serious adverse events occurred in one patient during treatment with 10 mg of ulipristal acetate (uterine hemorrhage) and in one patient during receipt of placebo (fibroid protruding through the cervix). Headache and breast tenderness were the most common adverse events associated with ulipristal acetate but did not occur significantly more frequently than with placebo. CONCLUSIONS: Treatment with ulipristal acetate for 13 weeks effectively controlled excessive bleeding due to uterine fibroids and reduced the size of the fibroids. (Funded by PregLem; ClinicalTrials.gov number, NCT00755755.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
The short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Nonparametric Statistical Methods.
Knott, M., Hollander, M., & Wolfe, D. A. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344557 · Cited by 2,662
Hematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851
Assessment of menstrual blood loss using a pictorial chart
HIGHAM, J. M., O'BRIEN, P. M. S., & SHAW, R. W. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb16249.x · Cited by 1,116
Uterine Myomas: An Overview of Development, Clinical Features, and Management
Wallach, E. E., & Vlahos, N. F. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000136079.62513.39 · Cited by 540
Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids
Lethaby, A., Vollenhoven, B., & Sowter, M. C. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000547 · Cited by 356
Fibroids and female reproduction: a critical analysis of the evidence
Somigliana, E., Vercellini, P., Daguati, R., Pasin, R., De Giorgi, O., & Crosignani, P. G. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm013 · Cited by 351
What are the implications of myomas on fertility?
Donnez, J., & Jadoul, P. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1424 · Cited by 350
Self-citation
Cited by
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Self-citationBulun, S. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1209993 · Cited by 703
Epidemiology and management of uterine fibroids
Giuliani, E., As‐Sanie, S., & Marsh, E. E. (2020) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13102 · Cited by 674
The Management of Uterine Leiomyomas
Vilos, G. A., Allaire, C., Laberge, P.-Y., Leyland, N., Vilos, A. G., Murji, A., & Chen, I. (2015) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30338-8 · Cited by 642
Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar, S., Gupta, D., & Vollenhoven, B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.43 · Cited by 531
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Menstruation: science and society
Critchley, H. O. D., Babayev, E., Bulun, S. E., Clark, S., Garcia-Grau, I., Gregersen, P. K., Kilcoyne, A., Kim, J.-Y. J., Lavender, M., Marsh, E. E., et al. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.06.004 · Cited by 448
Uterine fibroids: current perspectives
Khan, A., Shehmar, M., & Gupta, J. (2014) · International Journal of Women's Health · doi:10.2147/ijwh.s51083 · Cited by 406
Stewart, E. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmcp1411029 · Cited by 403
Role of nuclear progesterone receptor isoforms in uterine pathophysiology
Patel, B., Elguero, S., Thakore, S., Dahoud, W., Bedaiwy, M., & Mesiano, S. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu056 · Cited by 353
Uterine artery embolization for symptomatic uterine fibroids
Gupta, J. K., Sinha, A., Lumsden, M. A., & Hickey, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005073.pub2 · Cited by 350
Epidemiology of Uterine Fibroids: From Menarche to Menopause
WISE, L. A., & LAUGHLIN-TOMMASO, S. K. (2016) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000164 · Cited by 339
Long-term treatment of uterine fibroids with ulipristal acetate☆
Donnez, J., Vázquez, F., Tomaszewski, J., Nouri, K., Bouchard, P., Fauser, B. C. J. M., Barlow, D. H., Palacios, S., Donnez, O., Bestel, E., et al. (2014) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.02.008 · Cited by 332
Self-citationExtracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics
Islam, M. S., Ciavattini, A., Petraglia, F., Castellucci, M., & Ciarmela, P. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx032 · Cited by 321
Tolerability of different oral iron supplements: a systematic review
Cancelo-Hidalgo, M. J., Castelo-Branco, C., Palacios, S., Haya-Palazuelos, J., Ciria-Recasens, M., Manasanch, J., & Pérez-Edo, L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761599 · Cited by 320
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Epidemiology of Uterine Myomas: A Review.
Sparić, R., Mirković, L., Malvası, A., & Tinelli, A. (2016) · PubMed · doi:10.22074/ijfs.2015.4599 · Cited by 276
Uterine artery embolization for symptomatic uterine fibroids
Gupta, J. K., Sinha, A., Lumsden, M. A., & Hickey, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005073.pub4 · Cited by 269
Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids
Donnez, J., Hudecek, R., Donnez, O., Matule, D., Arhendt, H.-J., Zatik, J., Kasilovskiene, Z., Dumitrascu, M. C., Fernandez, H., Barlow, D. H., et al. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.10.038 · Cited by 216
Self-citationSelective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
Whitaker, L. H. R., Murray, A. A., Matthews, R., Shaw, G., Williams, A. R. W., Saunders, P. T. K., & Critchley, H. O. D. (2017) · Human Reproduction · doi:10.1093/humrep/dew359 · Cited by 77
Conservative management of uterine adenomyosis: medical vs. surgical approach
Stratopoulou, C. A., Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214878 · Cited by 62
Self-citationGonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis
Donnez, O., & Donnez, J. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.04.017 · Cited by 58
Self-citationDonnez, J., & Dolmans, M.-M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.05.017 · Cited by 50
Self-citationLiang, B., Wu, L., Xu, H., Cheung, C. W., Fung, W. Y., Wong, S. W., & Wang, C. C. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0347-9 · Cited by 41
Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids
Yin, H., Lo, J. H., Kim, J.-Y., Marsh, E. E., Kim, J. J., Ghosh, A. K., Bulun, S., & Chakravarti, D. (2013) · Molecular Endocrinology · doi:10.1210/me.2012-1305 · Cited by 31
Ulipristal Acetate Prior to Surgery for Endometriosis
Singh, S. S., Evans, D., McDonald, S., Senterman, M., & Strickland, S. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00146-1 · Cited by 10
“To date, PAECs appear to be benign and reversible in eutopic endometrium [1, 3, 11, 13].”
Background
Metadata
- Authors
- Donnez, J., Tatarchuk, T. F., Bouchard, P., Puscasiu, L., Zakharenko, N. F., Ivanova, T., Ugocsai, G., Mara, M., Jilla, M. P., Bestel, E., Terrill, P., Osterloh, I., & Loumaye, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-02-02
- Volume
- 366
- Issue
- 5
- Pages
- 409-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2106587450
- Cited by
- 680
- References
- 33
- FWCI
- 71.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.